로딩 중…
지수 로딩 중…
LENZ Therapeutics, Inc.
LENZ· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$5.00-5.75%
2026-08-03
Financials
Valuation Metrics
LENZ Therapeutics, Inc.'s Market Cap is $157M. At end of 2025 it was $457M. Ranked #3053 of 3,112 in US market (top 98%), #1396 of 1,445 on NASDAQ (top 97%), #260 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $157M | US#3,053/3,112 Sec#260/269 |
| Revenue | $21M | US#2,901/3,112 Sec#172/269 |
| Net Income | $-109M | US—/3,112 Sec—/269 |
| Total Assets | $273M | US#2,923/3,112 Sec#225/269 |
| Net Assets | $246M | US#2,646/3,112 Sec#177/269 |
| Value | ||
| P/B | 0.64x | US#113/3,112 Sec#3/269 |
| P/S | 7.46x | US#2,533/3,112 Sec#106/269 |
| FCF Yield | -55.83% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -44.22% | US#2,714/3,112 Sec#162/269 |
| ROA | -39.99% | US#2,926/3,112 Sec#192/269 |
| Op. Margin | -563.83% | US#2,899/3,112 Sec#163/269 |
| Financial Health | ||
| Debt Ratio | 10.57% | US#119/3,112 Sec#52/269 |
| Total Debt | $673000.00 | US#2,943/3,112 Sec#252/269 |
| FCF | $-87M | US#2,563/3,112 Sec#141/269 |
| Cash | $25M | US#2,815/3,112 Sec#255/269 |
| Current Ratio | 10.40x | US#239/3,112 Sec#76/269 |
| Performance | ||
| 1Y Return | -83.33% | US#3,121/3,112 Sec#267/269 |
| 1M Return | -15.20% | US#2,819/3,112 Sec#203/269 |
| From 52W High | -90.09% | US#3,112/3,112 Sec#269/269 |
| 1Y MDD | -90.05% | US#3,108/3,112 Sec#269/269 |
| Trading | ||
| Volume | 1,007,700 shares | US#1,462/3,112 Sec#144/269 |
| Trading Value | $5M | US#2,660/3,112 Sec#219/269 |
| Per Share | ||
| EPS | $-1.62 | US—/3,112 Sec—/269 |
| BPS | $6.79 | US#2,062/3,112 Sec#106/269 |